This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

Novartis Stock Hits New 52-Week High (NVS)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK (
TheStreet) --
Novartis (NYSE:
NVS) hit a new 52-week high Thursday as it is currently trading at $65.71, above its previous 52-week high of $65.65 with 319,104 shares traded as of 10:25 a.m. ET. Average volume has been 1.5 million shares over the past 30 days.

Novartis has a market cap of $157.77 billion and is part of the health care sector and drugs industry. Shares are up 3% year to date as of the close of trading on Wednesday.

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. The company has a P/E ratio of 17.3, below the S&P 500 P/E ratio of 17.7.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Novartis as a
buy. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, solid stock price performance, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full
Novartis Ratings Report.